ProCE Banner Activity

CME

Incorporating the Latest Therapeutic Strategies for HCC: Collaborating to Optimize Patient Outcomes

Multimedia
Watch this CME-certified on-demand Webcast of a CCO symposium at AASLD 2019 to gain expert perspectives on the evolving treatment landscape for HCC, with a focus on first-line and second-line systemic therapy for advanced/unresectable disease.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: January 07, 2020

Expiration: January 06, 2021

No longer available for credit.

Share

Faculty

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Anthony El-Khoueiry

Anthony El-Khoueiry, MD

Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California

Andrew X. Zhu

Andrew X. Zhu, MD, PhD, FACP

Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Bristol Myers Squibb

Eisai

Exelixis

Merck Oncology

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with hepatocellular carcinoma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
  • Collaborate with the multidisciplinary team to integrate emerging targeted agents and immuno-oncology regimens for HCC into routine practice as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with targeted agents and immunotherapy in patients with HCC
  • Refer appropriate patients with HCC to select ongoing clinical trials of novel agents and strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Lilly, Merck, Novartis, Pfizer, and Roche/Genentech.

Faculty Disclosure

Primary Author

Anthony El-Khoueiry, MD

Associate Professor of Medicine
Division of Medical Oncology, Keck School of Medicine
Norris Comprehensive Cancer Center, University of Southern California
Los Angeles, California

Anthony El-Khoueiry, MD, has disclosed that he has received funds for research support from AstraZeneca, Astex, and Merck and consulting fees from Agenus, Bayer, Bristol-Myers Squibb, Eisai, and Merck.

Andrew X. Zhu, MD, PhD, FACP

Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Andrew X. Zhu, MD, PhD, FACP, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Lilly, Merck, and Roche/Genentech.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 07, 2020, through January 06, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the multidisciplinary treatment of patients with hepatocellular carcinoma.